Replies to post #139420 on Biotech Values

[dav1234]

ONTY offering..11.75 mil shares @ $4, not bad considering

[DewDiligence]

ONTY—to finance AFTER the failed IA2 is clear proof that despite what Krikman said later, they thought there were decent chances of hitting on the second look. That would be inconsistent with some minute alpha spend.

I agree with that.